This Article Full Text (PDF) All Versions of this Article: 0897190008322249v1 22/1/75    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Epstein, B. J. Articles by Taylor, J. R. Search for Related Content Social Bookmarking                         What's this?

Osteoarthritis: An Update on Data Currently Reshaping Practice

Colleges of Pharmacy and Medicine, University of Florida, Gainesville, Epstein{at}cop.ufl.edu, East Coast Institute for Research, Jacksonville, Florida

James R. Taylor, PharmD, CDE

College of Pharmacy, University of Florida, Gainesville, Florida

Osteoarthritis is common, has considerable health consequences, and will affect increasing numbers of persons in coming years. Nonpharmacological interventions are of paramount importance in achieving adequate symptom control. Acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) play a pivotal role in osteoarthritis pharmacotherapy. Acetaminophen, due to its safety profile, should be adequately trialed before resorting to NSAIDs. NSAIDs and celecoxib, a selective inhibitor of cyclooxygenase-2, should be selected thoughtfully so as to balance the likelihood of treatment success with gastrointestinal bleeding and cardiovascular events. Celecoxib may be used when the risk for gastrointestinal bleeding is high and the risk of cardiovascular events low. Otherwise, NSAIDs, usually naproxen, should be paired with a gastroprotective agent. Topical NSAIDs, including a recently approved diclofenac patch and gel, may also be useful when systemic exposure is undesirable. The role of glucosamine and chondroitin is controversial and the data conflicting. Other modalities, such as tramadol, opioids, and viscosupplementation should be tailored to the patient and clinical situation. Appropriate deployment of agents in the osteoarthritis armamentarium can maximize efficacy and safety thereby improving the disease burden for patients.

Key Words: arthritis • osteoarthritis • nonsteroidal anti-inflammatory drugs • acetaminophen • cyclooxygenase 2 inhibitors

This version was published on February 1, 2009

Journal of Pharmacy Practice, Vol. 22, No. 1, 75-85 (2009)
DOI: 10.1177/0897190008322249


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?